Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-labelled, Bridging Phase Ⅲ Clinical Trial to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine in Healthy Population Aged From 3 to 11 Years

NCT05137418 is registered in ClinicalTrials.gov with Sinovac Research and Development Co., Ltd. as lead sponsor.

NCT NCT05137418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05137418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-labelled, Bridging Phase Ⅲ Clinical Trial to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine in Healthy Population Aged From 3 to 11 Years
Lead sponsor
Sinovac Research and Development Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
November 27, 2021
Completion date
January 27, 2023
Enrollment
1,000 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19